These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11302413)

  • 41. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Streptococcus pneumoniae resistance to fluoroquinolones.
    Wise R; Brenwald N; Gill M; Fraise A
    Lancet; 1996 Dec; 348(9042):1660. PubMed ID: 8962006
    [No Abstract]   [Full Text] [Related]  

  • 44. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
    Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?
    Nuermberger EL; Bishai WR
    Clin Infect Dis; 2004 May; 38 Suppl 4():S363-71. PubMed ID: 15127371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J; Ewig S; Kresken M
    Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The approach to treatment of invasive pneumococcal disease in the 1990s.
    Knapp KM; Schutze GE
    J Ark Med Soc; 1997 Nov; 94(6):263-6. PubMed ID: 9392928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of nasopharyngeal antibiotic-resistant pneumococcal carriage in children attending private paediatric practices in Johannesburg.
    Huebner RE; Wasas AD; Klugman KP;
    S Afr Med J; 2000 Nov; 90(11):1116-21. PubMed ID: 11196033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news.
    Low DE
    Clin Infect Dis; 2005 Aug; 41 Suppl 4():S228-33. PubMed ID: 16032557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance among Streptococcus pneumoniae: patterns, mechanisms, interpreting the breakpoints.
    Brueggemann AB; Doern GV
    Am J Manag Care; 2000 Dec; 6(23 Suppl):S1189-96. PubMed ID: 11187442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
    Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of antibiotic-resistant pneumococcal infections.
    Klugman KP
    J Antimicrob Chemother; 1994 Aug; 34(2):191-3. PubMed ID: 7814279
    [No Abstract]   [Full Text] [Related]  

  • 55. New quinolones--a fresh answer to the pneumococcus.
    Cubbon MD; Masterton RG
    J Antimicrob Chemother; 2000 Dec; 46(6):869-72. PubMed ID: 11102402
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of resistance and impact on appropriate antimicrobial use.
    DeBellis RJ
    Am J Ther; 2004; 11 Suppl 1():S1-8. PubMed ID: 23570155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct antimicrobial activity of antithrombin?
    Wiedermann CJ; Djanani A
    Crit Care; 2010; 14(5):440. PubMed ID: 20854649
    [No Abstract]   [Full Text] [Related]  

  • 58. Perspectives on newer oral antimicrobials: what do they add?
    Harrison CJ
    Pediatr Infect Dis J; 1995 May; 14(5):436-44. PubMed ID: 7638034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meeting the discovery challenge of drug-resistant infections: progress and focusing resources.
    Dougan G; Dowson C; Overington J;
    Drug Discov Today; 2019 Feb; 24(2):452-461. PubMed ID: 30476550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Have guidelines had an impact on antimicrobial resistance?
    Garau J
    Semin Respir Infect; 2001 Sep; 16(3):210-4. PubMed ID: 11562901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.